What you need to know
- Jersey Shore University Medical Center recently joined Hackensack University Medical Center as the only medical centers in the tristate area to offer the world’s first heart failure neuromodulation device Barostim Neo™.
- The Barostim Neo offers a groundbreaking treatment alternative for Congestive Heart Failure (CHF) patients.
The FDA accelerated this innovative technology to market because the device has been proven to be an effective alternative for patients with CHF who are ineligible for other forms of therapy such as Cardiac Resynchronization Therapy (CRT).
“Patients with CHF suffer from shortness of breath, poor quality of life, and are limited to mild daily activity. The best part is that the Barostim NEO is a safe, 45 minute, minimally invasive procedure and our patients can be admitted, receive the device, and be discharged all in the same day.”Jesus Almendral, M.D., FACC, medical director, Advanced Heart Failure Program, Jersey Shore University Medical Center
More details about Barostim NEO
The Barostim NEO is the only technology that targets cardiovascular disease at the source, the autonomic nervous system. This leading-edge device has the unique ability to improve heart performance, improve quality of life, increase mobility, reduce hospital readmissions as well as reduce the amount of medications patients take.